📊 BFRIW Key Takeaways
Investment Thesis
Biofrontera demonstrates deteriorating fundamental health despite modest revenue growth. Severe cash burn of $13.4M annually combined with negative profitability across all metrics suggests the company is consuming capital at an unsustainable rate. With only $6.4M in cash and negative operating cash flow, the company faces significant liquidity pressure without a clear path to profitability.
BFRIW Strengths
- Revenue growth of 11.7% year-over-year shows top-line expansion
- Positive cash position of $6.4M provides some operational runway
- Low leverage with 0.00x debt-to-equity ratio reduces financial stress
BFRIW Risks
- Severe cash burn of $13.4M annually with only 5.7 months of runway at current burn rate
- Consistently negative profitability with -25.3% net margin and -27.2% operating margin
- Operating cash flow of -$13.4M indicates core business cannot fund operations
- Negative ROE of -100.5% and ROA of -36.9% demonstrate capital destruction
- Free cash flow margin of -32.0% indicates value destruction on every dollar of revenue
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF
- Monthly cash burn rate and cash runway remaining
- Revenue growth sustainability and gross margin if disclosed
- Operating leverage improvements and timeline to EBITDA profitability
BFRIW Financial Metrics
💡 AI Analyst Insight
Biofrontera Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BFRIW Profitability Ratios
BFRIW vs Healthcare Sector
How Biofrontera Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BFRIW Balance Sheet & Liquidity
BFRIW 5-Year Financial Trend
5-Year Trend Summary: Biofrontera Inc.'s revenue has grown significantly by 73% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.22 indicates the company is currently unprofitable.
BFRIW Growth Metrics (YoY)
BFRIW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $7.0M | -$5.7M | $-0.62 |
| Q2 2025 | $7.8M | -$257.0K | $-0.05 |
| Q1 2025 | $7.9M | -$4.2M | $-0.47 |
| Q3 2024 | $8.9M | -$5.7M | $-0.98 |
| Q2 2024 | $5.8M | -$257.0K | $-0.05 |
| Q1 2024 | $7.9M | -$7.5M | $-2.88 |
| Q3 2023 | $4.3M | $2.1M | $2.19 |
| Q2 2023 | $4.5M | -$850.0K | $-0.90 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BFRIW Capital Allocation
BFRIW SEC Filings
Access official SEC EDGAR filings for Biofrontera Inc. (CIK: 0001858685)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BFRIW
What is the AI rating for BFRIW?
Biofrontera Inc. (BFRIW) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BFRIW's key strengths?
Revenue growth of 11.7% year-over-year shows top-line expansion. Positive cash position of $6.4M provides some operational runway.
What are the risks of investing in BFRIW?
Severe cash burn of $13.4M annually with only 5.7 months of runway at current burn rate. Consistently negative profitability with -25.3% net margin and -27.2% operating margin.
What is BFRIW's revenue and growth?
Biofrontera Inc. reported revenue of $41.7M.
Does BFRIW pay dividends?
Biofrontera Inc. does not currently pay dividends.
Where can I find BFRIW SEC filings?
Official SEC filings for Biofrontera Inc. (CIK: 0001858685) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BFRIW's EPS?
Biofrontera Inc. has a diluted EPS of $-1.04.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.